Pharmaceutical

ESMO 2024: Enhertu to eclipse SOC for HER2+ breast cancer with brain metastases

GlobalData forecasts predict Enhertu will retain its dominant market position in the ADC treatment landscape.

Sep 16, 2024 - 04:00
ESMO 2024: Enhertu to eclipse SOC for HER2+ breast cancer with brain metastases
GlobalData forecasts predict Enhertu will retain its dominant market position in the ADC treatment landscape.
Read the original article

Tags:

Previous Article

ESMO 2024: TIGIT race tightens with first look at GSK/iTeos’s TIGIT in NSCLC

Next Article

Express Scripts sues FTC and demands drug pricing report retraction

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Emotional dry cleaning: A writer helps doctors share their stories — and their pain

Emotional dry cleaning: A writer helps doctors share th...

Aug 31, 2023

Opinion: Missing data is making it difficult for the pharmaceutical industry to help LGBTQ+ people

Opinion: Missing data is making it difficult for the ph...

Mar 4, 2024

AD/PD 2024: Vaxxinity reveals Phase I success with Parkinson’s vaccine  

AD/PD 2024: Vaxxinity reveals Phase I success with Park...

Mar 9, 2024